“…This case rule was originally developed for the SCL-90-R and subsequently recommended for the BSI and BSI-18, though the manual does not present any empirical support for the case-rule as applied to the BSI-18. Following common practice for the BSI (e.g., Brown, Whiteley, Harper, Nichols, & Nieves, 2015; Endermann, 2005) users of the BSI-18 in oncology (Merport & Recklitis, 2012; Michel et al, 2010; Zabora et al, 2001; Zeltzer et al, 2009) and other populations (Hart et al, 2014; Hopp, Anderson, Krumholz, Gruber-Baldini, & Shulman, 2012; Mustanski, Garofalo, Herrick, & Donenberg, 2007; Petkus et al, 2010) commonly define overall significant symptoms on the BSI-18 using the GSI scale alone, classifying respondent with GSI t-score ≥ 63 as having clinically significant symptoms. Both the published BSI-18 case-rule criteria (t-score score ≥ 63 on the GSI, or any two of symptom scales) and the conventional case-rule of GSI t-score ≥ 63 were evaluated in this study.…”